ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2383

A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis

Chiara Stagnaro1, Claudia Ferrari2, Rosaria Talarico3, Camillo Giacomelli1, Stefano Bombardieri1 and Laura Bazzichi1, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy, 3Rheumatology Unit, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologics, Rheumatoid arthritis (RA), therapy and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: In the last few year the introduction of biological agents has radically changed  the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no single drug is able to control all patients with RA and it is known that each drug may be poorly effective in a sizable proportion of the treated patients. For these reasons the early identification of clinical responder patients may represent a crucial advantage for either clinical and socioeconomic reasons. Recently, mathematic algorithms, based on classical clinical parameters, have been proposed  to predict the clinical response to anti TNF and DMARDs. In the present study we have applied the mathematic algorithm  proposed to predict early response to anti TNF on our cohort of RA patients treated with tocilizumab (TCZ)

Methods: We collected the data of 61 RA patients (male: female= 52:9; mean age ± SD 50.0 ± 16.0; DAS28 at the onset:5.2±0.7; DAS28 at 1year: 1.5±0.35) followed in our unit and treated with TCZ  from Jan 2010 to Jan 2013, with a follow up of at least 12 months. The mathematic algorithm was based on the following parameters: Tender Joint, Swollen Joint, Illness activity VAS by Physician and patient, Pain VAS, ESR and CRP. It was applied to calculate the putative responders at one month of treatment and this value was compared with the DAS 28 at one month and at one year of therapy. The patients were classified as good responders if they had a delta DAS28> 1.2

Results: The mathematical model allows to predict 90% of the final responders for all treated patients, with the occurrence of 3 false negative patients. Moreover, after 1 month of therapy a delta DAS 28>1.2 was recorded in 30% of patients, while at one it was found in 88% of cases

Conclusion: these data suggest that the mathematical algorithm proposed to predict the clinical response to anti TNF, may be apply in the routine clinical practice also to RA patients treated with TCZ. Although we need further results from ongoing prospective clinical studies, it is desirable that this simple mathematical model will use to predict at one month the response in almost RA patients


Disclosure:

C. Stagnaro,
None;

C. Ferrari,
None;

R. Talarico,
None;

C. Giacomelli,
None;

S. Bombardieri,
None;

L. Bazzichi,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-useful-mathematical-model-able-to-predict-the-early-response-to-tocilizumab-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology